Nasus provides targeted symptomatic relief and supportive care for nasal discomfort.

---

Supportive Care for Dryness and Secretion Management

Applied across domains where additional symptomatic support is needed, the preparation is relevant for easing symptoms that interfere with daily comfort, such as nasal dryness and irritation. It is commonly used across conditions characterized by periods of heightened symptoms to address the build-up of thick, crusty mucus and associated stuffy nose that create noticeable physiological strain. The preparation contributes to improving comfort during these symptomatic periods.

---

Adjunctive Use in Clinical Scenarios

Nasus is relevant for easing congestion associated with Allergic Rhinitis, Sinusitis, and during viral upper respiratory infections. By facilitating the flushing out of environmental irritants and supporting the removal process, it is applied in scenarios where additional management of discomfort is required, such as in post-operative nasal care, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supportive Relief for Nasal Discomfort

Regulatory References

1. NIH MedlinePlus Medical Encyclopedia overview

Who Can and Cannot Use Nasus?

Eligibility for Nasus is strictly defined by regulatory documents, focusing on patient status and specific population groups. As a topical nasal solution, its eligibility profile is primarily determined by age and hypersensitivity status, with minimal systemic restrictions.

---

Official Eligibility Status

Population Group	Regulatory Status	Constraint Basis
Adults and Adolescents	Permitted	Standard labeled use.
Pregnant Women	Permitted	Minimal systemic absorption; no contraindications documented.
Breastfeeding Women	Permitted	Minimal systemic absorption; no contraindications documented.

---

Absolute Non-Eligibility (Contraindications)

Nasus is contraindicated and must not be used by patients with a known hypersensitivity or documented allergy to any of its components. This restriction specifically includes the active ingredient Sodium Chloride and the preservative Benzalkonium Chloride (BAC).

Age-Related Restrictions

Use in children below the minimum labeled age (e.g., under 6 years) is officially classified as not recommended or use not established in regulatory documentation. This is a common restriction for combination nasal products containing preservatives like BAC.

The official regulatory profile for Nasus is defined by a lack of documented systemic pharmacokinetic interactions with other medicinal products. This is attributed to the minimal systemic absorption of its active components, Sodium Chloride and Benzalkonium Chloride, following intranasal administration. Accordingly, regulatory documentation specifies no systemic exposure-modifying effects, such as alterations to CYP enzyme function or P-glycoprotein transporter activity.

No formal drug–drug combinations are strictly contraindicated in the regulatory labeling based on systemic interaction risk. Furthermore, official documents confirm no specific timing-based interaction rules or mandatory dose separation requirements are documented for Nasus and other medicines. The profile also lists no established interactions with food, alcohol, or herbal products.

The only documented interaction pattern is classified as a local pharmacodynamic effect. Co-administration with other intranasal preparations, including nasal corticosteroids or nasal decongestants, is associated with a potential for additive local irritation. The resulting effect of this interaction is described in regulatory sources as an increase in the likelihood of local nasal dryness or mucosal irritation. Finally, no population-specific interaction considerations are noted in official labeling for patients with conditions such as hepatic or renal impairment.

Nasus (NS002, an investigational product) is a powder-based intranasal formulation of epinephrine. Epinephrine functions as a non-selective adrenergic receptor agonist that targets alpha and beta subtypes (alpha1, alpha2, beta1, beta2, beta3) located on various cell types throughout the body.

Following nasal administration, epinephrine is rapidly absorbed into the systemic circulation through the rich vascular network of the nasal mucosa. At the cellular level, the agent's binding to alpha1 adrenergic receptors on vascular smooth muscle cells activates the Gq signaling cascade, leading to an increase in intracellular Ca^2+ concentration and subsequent vasoconstriction. Simultaneously, binding to beta1 adrenergic receptors in the heart, coupled to the Gs pathway, activates adenylyl cyclase, increases cyclic AMP ( cAMP), and results in an increase in heart rate and myocardial contractility. The interaction with beta2 adrenergic receptors on bronchial smooth muscle cells also elevates cAMP, promoting bronchodilation. The aggregate systemic physiological consequence involves the modulation of peripheral vascular tone and cardiac output.

The administration of Nasus involves a method for using the 0.65% Sodium Chloride aqueous solution. The product is designated for the intranasal route of administration, ensuring the solution is delivered directly to the nasal passages.

Administration and Dosage

The standardized dosing is two squeezes or two sprays applied to each nostril during a single application. This regimen provides the intended volume of solution per use. As the product is manufactured as a pre-mixed solution, no preparation, dilution, or reconstitution is required prior to use. Administration is defined by an as-needed frequency pattern, allowing for the repetition of the application sequence as required, with the product suitable for frequent daily use.

Population-Specific Delivery

The method of delivery varies based on age. For infants, the solution is administered via the drop application method to ensure gentle delivery. In contrast, for both children and adults, the application is executed using the spray or stream function of the device.

Procedural Constraints

General hygiene practices are focused on device maintenance. To prevent the spread of contamination, the dispenser should not be shared with other individuals. The tip of the dispenser must also not be contaminated during the application process to maintain the integrity of the solution.

Research Evidence / Overview of Studies for Nasus

Evidence for Supportive Care in Allergic Rhinitis

Research on Nasus, particularly its saline solution component, has been applied in studies examining patient-reported experiences related to Allergic Rhinitis (AR). The core evidence in this area comes from Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate saline solutions in research settings, often used as an adjunct to other study protocols.

Researchers explored measurements of symptoms, often tracking changes in symptom intensity using standardized scales. Studies report the patterns observed in the measured outcomes of the study populations over the defined study period, noting measurements of change in symptom scores. Follow-up durations were typically short-term, limited to a few weeks or months.

Evidence for Use in Sinusitis and Post-Operative Care

The use of saline solutions for supportive care was studied for conditions involving periods of heightened symptoms, specifically Sinusitis (acute and chronic). Research also explored the application of saline for hygiene following nasal surgery. RCTs and observational cohorts focused on how saline solutions were observed in conditions characterized by cycles of stability and flare-ups, primarily including adults.

Findings described patterns observed in these studies, positioning the use of saline solutions as an adjunctive measure, meaning it was evaluated as a co-administered part of a study protocol. Evidence quality varies across studies, and the concentration of the saline solution was associated with different measured outcomes.

Research on General Nasal Hygiene and Mucosal Moisturization

The use of the saline component for fundamental nasal hygiene and moisture maintenance has been extensively evaluated in physiological and non-randomized studies. Studies focused on outcomes related to mucosal hydration and the measurement of functional changes in the nasal lining. Research provides insight into short-term changes and describes the physical process of moisture delivery and osmotic action in a research context. However, the evidence is limited and supported primarily by physiological principles.

Research Gaps and Areas of Uncertainty

Comparative evidence is lacking in high-quality trials specifically comparing the efficacy of the low-volume nasal spray formulation (like Nasus) against high-volume irrigation methods. Research also provides context but not individual predictions regarding the long-term physiological changes that may be associated with the Benzalkonium Chloride (BAC) preservative component. Findings highlight that research provides insight into the established physical principles of saline solutions, but certainty remains low for the comparative value of different administration methods.

Key Studies & References

1. Efficacy of nasal irrigation with hypertonic saline on chronic rhinosinusitis: systematic review and meta-analysis
2. SALINE NASAL SPRAY (OTC Drug Label Information)

Common questions about Nasus (FAQ)

---

Q: Can Nasus cause a change in taste or smell?

Official regulatory documents indicate that Nasus may cause an Abnormal taste (Dysgeusia) as a rare side effect. However, a change in the sense of smell is not typically documented in the common adverse reaction summaries.

---

Q: Will Nasus affect my ability to drive or operate machinery?

According to the official product information, Nasus works locally in the nose and does not list Central Nervous System (CNS) side effects. As a result, the product is not anticipated to affect the ability to drive or operate machinery based on its safety profile.

---

Q: Can Nasus be taken with alcohol?

Official regulatory documentation confirms that there are no established systemic interactions between Nasus and alcohol. There are also no specific warnings regarding its use with food or herbal products.

---

Q: Is it normal to feel a burning or stinging sensation in the nose when using Nasus?

Similar saline-based products often list a brief stinging or burning sensation in the nose as a common and temporary effect right after administration. If this irritation is persistent or severe, it is important to contact a healthcare professional.

---

Q: What should I do if Nasus causes me to sneeze right after I use it?

Sneezing is listed as a possible side effect of the product. The official directions emphasize correct administration technique. If sneezing consistently interferes with proper administration, you may wish to discuss this with a healthcare professional.

---

Q: Is there a risk of becoming dependent on Nasus if it's used frequently?

Official information indicates the product is non-habit forming due to its saline-based nature and is generally safe for frequent daily use.

---

Q: How long does the effect of Nasus typically last?

The regulatory mechanism describes the action as a local moisturizing and physical cleansing effect. Regulatory summaries do not specify a fixed duration of relief but indicate the product is administered as-needed to maintain comfort.

---

Q: Does Nasus lose its effectiveness if the user has a cold or a stuffy nose?

The product is indicated for use in relieving dry nasal passages, and it works by thinning and washing away accumulated mucus, since it is indicated for use in relieving dry nasal passages, which often accompany colds.

---

Q: Can elderly patients use Nasus without special concern?

The product is permitted for use by adults. Due to minimal systemic absorption (it primarily stays local to the nose), there are no specific contraindications or special warnings for the elderly population documented in the official labeling.

---

Q: Is Nasus a steroid, or does it belong to a different drug class?

Nasus is not a steroid. It is officially classified as a Saline Solution and a Quaternary Ammonium Compound Antiseptic due to the combination of Sodium Chloride and Benzalkonium Chloride.

---

Q: How is Nasus different from other medicines used for the same conditions?

Regulatory documents define Nasus as a non-medicated saline/antiseptic solution used for nasal moisturizing and physical cleansing. This mechanism implicitly distinguishes it from other medicated products used for nasal conditions, such as prescription steroids or antihistamines.

---

Q: Is there research on the long-term physiological changes associated with the Benzalkonium Chloride (BAC) preservative component?

Official safety summaries note that the preservative Benzalkonium Chloride has been associated with the potential for swelling inside the nose (oedema of the nasal mucosa), particularly with use for a long period of time. If you anticipate continuous long-term use, it is appropriate to discuss the safety profile with a healthcare professional.

---

Q: Is the low-volume spray formulation (like Nasus) more effective than high-volume irrigation methods?

Official research summaries explicitly state that comparative evidence is currently lacking in high-quality trials. It is not currently possible to definitively compare the effectiveness of the low-volume nasal spray formulation against high-volume saline irrigation methods.

---

Q: What is the difference between the drug components in NS001 and NS002?

The approved product, Nasus (NS001), contains Sodium Chloride and Benzalkonium Chloride as its active components. NS002 is an investigational product that is an intranasal formulation of the drug epinephrine, which is used for different conditions.

---

Q: What is the research evidence for how effective Nasus is compared to injections?

The research conducted on the approved Nasus product (a saline solution) focuses on its supportive use in allergic rhinitis and sinusitis symptoms. This body of research does not include studies comparing its effectiveness to injectable medicines used for emergency conditions.

How to Store and Dispose of Nasus?

The storage and disposal instructions for Nasus, an aqueous nasal saline solution, are determined by regulatory labeling to maintain product stability and safety.

Storage Requirements

• Temperature: Store at controlled room temperature (20 C to 25 C or 68 F to 77 F). Do not freeze and avoid storage above 120 F.
• Protection: The product must be protected from excessive heat, moisture, and light.
• Container: Keep the medication in the original container and ensure the cap is tightly closed when not in use.
• Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Nasus should be conducted according to local environmental regulations. The recommended method is to use a drug take-back program or an authorized collection site, where available. The product must not be flushed down the toilet or sink.